

Vaccinia virus (strain Copenhagen) OPG125 Protein (His & Myc)

General Information

Synonyms:	OPG125;62 kDa protein;Scaffold protein OPG125;Rifampicin resistance protein
Protein Construction:	1-230 aa
Species:	VACV
Expression Host:	E. coli
Accession:	P68441
Molecular Weight:	33.2 kDa (predicted)
AA Sequence:	MNNTIINSLIGGDDSIKRSNVFAVDSQIPTLYMPQYISLSGVMTNDGPDNQAIASFEIRDQYITALNHLVLSLELPEVKGMGRFGYVPYVGYKGINHVSISCCNGVIWEIEGEELYNNCINNTIALKHSGYSSELNDISIGLTPNDTIKEPSTVYVYIKTPFDVEDTFSSLLKLSDSKITVTVTFNVPVSDIVIRDSSFDFFETFNKEFVYVPELSFIGYMVKNVQIKPSFIE

QC Testing

Biological Activity:	Activity has not been tested. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
Purity:	> 90% as determined by SDS-PAGE.
Endotoxin:	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation:	If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.

Preparation and Storage

Reconstitution:	Reconstitute the lyophilized protein in sterile deionized water. The product concentration should not be less than 100 μg/mL. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.
Stability & Storage:	Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. <small>Actual storage temperature shall be subject to the COA.</small>
Shipping:	In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

Scaffold protein which forms a transitory spherical honeycomb lattice providing curvature and rigidity to the

convex membrane of crescent and immature virions (IV). This association occurs concomitantly with viral membrane formation. Targeted by the drug rifampicin, which prevents the formation of this lattice, and hence virus morphogenesis. In the presence of rifampicin, irregularly shaped membranes that lack the honeycomb layer accumulate around areas of electron-dense viroplasm. This layer is lost from virions during maturation from IV to mature virion (MV), through the proteolysis of A17 N-terminus.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481